Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]
- Market Cap ₹ 1,902 Cr.
- Current Price ₹ 813
- High / Low ₹ 1,651 / 788
- Stock P/E 108
- Book Value ₹ 315
- Dividend Yield 0.25 %
- ROCE 7.02 %
- ROE 4.86 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 2.58 times its book value
- Company has a low return on equity of 12.2% over last 3 years.
- Dividend payout has been low at 9.93% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -7.15%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE Allcap BSE Commodities BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
136 | 206 | 263 | 300 | 434 | 424 | 394 | 371 | |
113 | 172 | 208 | 234 | 325 | 363 | 325 | 327 | |
Operating Profit | 23 | 34 | 55 | 67 | 109 | 61 | 69 | 45 |
OPM % | 17% | 17% | 21% | 22% | 25% | 14% | 17% | 12% |
1 | 1 | 1 | 5 | 9 | 2 | 7 | 7 | |
Interest | 3 | 4 | 4 | 4 | 5 | 9 | 7 | 1 |
Depreciation | 3 | 4 | 5 | 7 | 8 | 10 | 26 | 26 |
Profit before tax | 19 | 27 | 48 | 61 | 104 | 45 | 44 | 25 |
Tax % | 35% | 25% | 21% | 14% | 8% | -2% | 30% | |
12 | 21 | 38 | 52 | 96 | 45 | 30 | 18 | |
EPS in Rs | 15.30 | 25.56 | 47.03 | 26.02 | 43.25 | 20.52 | 12.97 | 7.54 |
Dividend Payout % | 0% | 0% | 0% | 19% | 5% | 10% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 9% |
TTM: | -19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | -17% |
TTM: | -64% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -31% |
1 Year: | -48% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 12% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 20 | 22 | 22 | 23 | 23 |
Reserves | 51 | 72 | 110 | 146 | 451 | 493 | 714 | 714 |
56 | 77 | 91 | 90 | 120 | 170 | 14 | 15 | |
28 | 31 | 41 | 59 | 65 | 74 | 67 | 54 | |
Total Liabilities | 144 | 188 | 249 | 315 | 658 | 759 | 819 | 807 |
57 | 67 | 111 | 120 | 160 | 196 | 427 | 425 | |
CWIP | 10 | 6 | 5 | 10 | 51 | 231 | 77 | 114 |
Investments | 1 | 0 | 0 | 0 | 0 | 0 | 10 | 0 |
76 | 115 | 133 | 185 | 447 | 332 | 305 | 268 | |
Total Assets | 144 | 188 | 249 | 315 | 658 | 759 | 819 | 807 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
13 | 7 | 25 | 20 | 20 | 28 | 98 | |
-30 | -17 | -40 | -21 | -197 | -101 | -121 | |
7 | 17 | 10 | -5 | 235 | 38 | 31 | |
Net Cash Flow | -10 | 8 | -5 | -6 | 59 | -36 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 77 | 73 | 69 | 110 | 48 | 73 | 65 |
Inventory Days | 148 | 114 | 175 | 173 | 319 | 262 | 320 |
Days Payable | 127 | 71 | 87 | 114 | 83 | 52 | 94 |
Cash Conversion Cycle | 99 | 116 | 157 | 169 | 283 | 283 | 291 |
Working Capital Days | 101 | 117 | 104 | 151 | 164 | 168 | 170 |
ROCE % | 22% | 28% | 28% | 26% | 9% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4 Dec - Schedule of investor meeting on December 10, 2024.
-
Announcement under Regulation 30 (LODR)-Credit Rating
6 Nov - CRISIL revises credit rating outlook to negative.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 Oct - Transcript of the earnings call held on 25 October 2024 post announcement of financial results of the Company for the quarter and half year ended …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Oct - Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Half year ended 30 September 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
25 Oct - Earnings call recording available on company website.
Annual reports
Concalls
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT REC
-
May 2024Transcript PPT REC
-
Jan 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Jul 2022Transcript PPT
-
Apr 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021TranscriptPPT
-
Sep 2021TranscriptPPT
Leading Chemical Manufacturer[1]
It is the largest manufacturer of Structure Directing Agents (SDA) for Zeolites in India.